Zum Inhalt springen

Compounded GLP-1 Recall and 'Research Use' Retatrutide Put Unapproved Weight-Loss Drugs Under Scrutiny

23.10.2026 · 22 Min.

Shownotes

Unapproved GLP-1 drugs are under pressure from several directions. Compounding pharmacy Apothecary Pharma voluntarily recalled 22 lots of compounded tirzepatide, the active ingredient in Zepbound and Mounjaro, citing "lack of assurance of sterility," and FDA classified the recall as Class II. A bipartisan group of senators led by Sen. Jim Banks wrote to the acting FDA commissioner on October 14, 2026, urging a crackdown on vendors using "for research use only" labels to sell retatrutide, Eli Lilly's investigational drug that is not FDA-approved, and citing a 265% rise in poisonings tied to illicit retatrutide reported by America's Poison Centers. CBS News reported that FDA received two adverse-event reports of deaths linked to products sold as retatrutide; the reports are unverified and do not prove the products caused the deaths. We also walk through FDA's own warnings: compounded drugs are not FDA-approved, retatrutide cannot be used in compounding, and FDA has flagged quality problems at overseas ingredient suppliers. We explain how compounded, counterfeit and "research use only" products differ from FDA-approved medicines, and what regulators, lawmakers and drugmakers are doing about them. Sources: - FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (updated Oct 1, 2026): https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss - Sen. Jim Banks press release and senators' letter to FDA (Oct 15, 2026): https://www.banks.senate.gov/news/press-releases/banks-urges-fda-to-crack-down-on-illicit-research-use-only-drugs/ - CBS News, reported deaths and bootleg retatrutide: https://www.cbsnews.com/news/deaths-reported-fda-bootleg-reta-weight-loss-drug/ - BioPharma Dive, Apothecary Pharma compounded tirzepatide recall (Oct 22, 2026): https://www.biopharmadive.com/news/glp1-obesity-drug-recall-apothecary-tirzepatide-zepbound/833712/ - USA TODAY, compounded GLP-1 recall and FDA actions (Oct 20, 2026): https://www.usatoday.com/story/money/personal-finance/healthcare/2026/10/20/fda-targets-copycat-glp-1-weight-loss-drugs/92343423007/ Cover photo: laboratory at the FDA White Oak campus, Building 64 (U.S. Food and Drug Administration, public domain, via Wikimedia Commons; cropped). This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. More at glp1newspaper.com

Alle Folgen von GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Einstellungen

Darstellung

Sprache

Bestimmt, welche Sender dir auf der Startseite zuerst gezeigt werden.

Verlauf

Zuletzt gehörte Sender und Folgen und deine letzten Suchen liegen nur in diesem Browser.

Hinweise

Ein kurzer Hinweis, wenn ein Podcast, dem du folgst, eine neue Folge hat. Einzelne Podcasts stellst du über die Glocke auf ihrer Seite ab.

Konto

Favoriten speichern – in der App und auf der Website.

Tastenkürzel

/
Suche öffnen
Leertaste
Abspielen oder anhalten
← →
Im Player: 15 s zurück, 30 s vor (Folgen) · im Regal: nächste Kachel
↑ ↓
Im Regal: Ziel innerhalb der Kachel
Pos1 / Ende
Im Regal: erste bzw. letzte Kachel
Esc
Fenster oder Menü schließen
?
Diese Übersicht
Läuft gerade

Zur Senderseite

Als Nächstes

    Folgen mit „Als Nächstes“ vormerken – sie laufen nach der aktuellen Folge.